The Future Of Clinical Trials In 2019 - AcriIndia

1
With evolution of old concepts and coming up of
new innovative concepts, the clinical trial
industry has seen a very exciting year in 2018.
Digital health and AI concepts have been the
main focus of the industry, with the concept of
patient connectivity and information exchange
being the new idea.

• The basic concept of patient information exchange
  is centred on enhancing communications between
  patients and sponsors, and tending to patients
  needs for information before, during, and after
  clinical trial participation. The patient is
  considered in study design, awareness is raised
  about clinical trials with patients in
  communities, supplementary materials are provided
  to patients during the trials, and data is given
  back to the patients after the completion of the
  trial. All of this improves patient experience
  in clinical trials. By the end of 2018, it has
  been identified that the clinical trial
  landscape is very competitive. This is why
  collaborative approaches with patients during
  study design is considered to be one of the most
  important aspects that attracts and retains
  patients by creating studies around their lives.
  There are certain organizations that are also
  supporting study sites with tools, resources, and
  information that can assist patients through the
  clinical trial journey.
• The internet and artificial intelligence are also
  being significantly used to maintain patient
  engagement with the studies. Digital health is of
  prime concern, where

2

• various factors ranging from wearable devices to
  digital biomarkers are being used. In addition,
  continuous data collections and the need for
  improved data quality is sure to drive digital
  transformation even further.
• Block chain is another element that is yet in the
  early stages in the biopharmaceutical industry,
  but yet has a lot of potential in clinical
  trials. It can be used for screening,
  recruitment, clinical trial registration, source
  documentation, and much more.
• Quality management analytics has also broken
  through many areas in clinical trials, and has
  also started to impact regulatory agencies. The
  biopharmaceutical industry continues to advance
  quality measures by incorporating quality
  tolerance limits to expand adherence with new
  guidelines. These limits impact protocol design,
  clinical study reports, and risks management.
• Risk based monitoring practices are starting to
  scale in the clinical trial industry, with the
  most commonly known key risk and performance
  indicators being quality indicators, cycle time
  indicators, and efficiency indicators. Such risk
  based monitoring service providers are offering
  targeted solutions today.
• With all of this been seen in 2018, what should
  we expect in the new year? On the patient
  information exchange and connectivity front, we
  expect to see more biopharmaceutical companies
  targeting recruitment, enrolment, and retention.
  In addition, clinical trial data exchange may
  not be seen with patients after the completion of
  the study. On the digital health front, we
  expect to see many new validations and measures
  using electronic digital reference objects. On
  the block chain front, we expect lesser block
  chain pilots. However, more of artificial
  intelligence based technologies are expected to
  be seen. All in all, many novel quality
  management concepts are expected to emerge with
  the coming year. But, one thing that is not
  going to change is the quality of clinical
  research education being provided through the
  clinical research diploma courses in Bangalore
  provided by professionals at Avigna Clinical
  Research Institute. Here, you can have yourself
  enrolled and get the finest quality education
  right from the comfort of your home, without
  compromising on your current lifestyle, job, and
  responsibilities!